The University of Queensland (UQ) researchers have unveiled remote care platform for the treatment of neurological disorders.

The university’s Queensland Brain Institute (QBI) has partnered with Neurosciences Queensland and Abbott Neuromodulation to develop the wireless neuro-stimulator for treatment of Parkinson’s, chronic depression and other psychiatric conditions.

The platform is designed to enable patients to gain access to the treatment from anywhere in the world.

Queensland Brain Institute professor Peter Silburn said: “We have shown that it is possible to minimise disruption to patients’ and carers’ lifestyles by increasing accessibility to the service, saving time and money.

“There are no cures for many of these conditions which often require life-long treatment and care, so for those people the device would be a game-changer.”

The digital platform facilitates the remote monitoring of patients as well as reduction of symptoms in real-time.

Besides, the remote care platform is developed to support data-driven clinical decisions and enhanced personalised treatment.

The digital health platform for remote neuromodulation systems has secured regulatory approval and rolled out in Australia in October last year.

Silburn said: “As we discover more about the biomarkers in brain-related disorders, we will refine neuromodulation systems to improve treatment for neuropsychiatric disorders like depression, obsessive-compulsive disorder, anorexia and Tourette’s syndrome, to name a just a few.”

The platform has also been adopted in the US by the Food and Drug Administration (FDA) and the European CE-Mark.

The researchers believe the technology may be used for several other conditions in the future.